United Therapeutics Files Q1 2025 10-Q

Ticker: UTHR · Form: 10-Q · Filed: Apr 30, 2025

Sentiment: neutral

Topics: 10-Q, financials, pharmaceuticals

TL;DR

UTHR Q1 2025 10-Q is in. Check financials.

AI Summary

United Therapeutics Corp. filed a 10-Q for the period ending March 31, 2025. The filing details financial information and business operations for the first quarter of 2025. Key financial data and operational updates are presented within this report.

Why It Matters

This filing provides investors and analysts with the latest financial performance and operational details for United Therapeutics Corp. during the first quarter of 2025.

Risk Assessment

Risk Level: low — This is a standard quarterly financial filing with no immediate red flags or significant new risks indicated.

Key Numbers

Key Players & Entities

FAQ

What is the total revenue for United Therapeutics for the quarter ended March 31, 2025?

The filing does not explicitly state the total revenue figure in the provided snippet. Further review of the full 10-Q document is required.

What were the net earnings for United Therapeutics during the first quarter of 2025?

The provided text does not contain specific net earnings figures for the first quarter of 2025. This information would be detailed within the full financial statements of the 10-Q.

What is the company's primary business segment as indicated in this filing?

The filing indicates the company operates within the 'PHARMACEUTICAL PREPARATIONS' industry, with SIC code 2834.

Where is United Therapeutics Corp. headquartered?

United Therapeutics Corp. is headquartered in Silver Spring, MD, with the zip code 20910.

What is the SEC file number for United Therapeutics Corp.?

The SEC file number for United Therapeutics Corp. is 000-26301.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on April 30, 2025 regarding UNITED THERAPEUTICS Corp (UTHR).

View full filing on EDGAR

View on Read The Filing